Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Retained Earnings (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Retained Earnings for 6 consecutive years, with -$331.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings fell 12.32% year-over-year to -$331.4 million, compared with a TTM value of -$331.4 million through Sep 2025, down 12.32%, and an annual FY2024 reading of -$35000.0, down 3600.0% over the prior year.
  • Retained Earnings was -$331.4 million for Q3 2025 at Ovid Therapeutics, down from -$319.2 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $5208.0 in Q2 2023 and bottomed at -$331.4 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$141.2 million, with a median of -$139.7 million recorded in 2021.
  • The sharpest move saw Retained Earnings soared 102.37% in 2023, then tumbled 7610036.7% in 2024.
  • Year by year, Retained Earnings stood at -$145.4 million in 2021, then soared by 99.97% to -$42187.0 in 2022, then skyrocketed by 102.37% to $1000.0 in 2023, then crashed by 3600.0% to -$35000.0 in 2024, then tumbled by 946757.14% to -$331.4 million in 2025.
  • Business Quant data shows Retained Earnings for OVID at -$331.4 million in Q3 2025, -$319.2 million in Q2 2025, and -$47000.0 in Q1 2025.